Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns by Cillóniz, Catia et al.
 International Journal of 
Molecular Sciences
Review
Microbial Etiology of Pneumonia: Epidemiology,
Diagnosis and Resistance Patterns
Catia Cilloniz 1, Ignacio Martin-Loeches 2, Carolina Garcia-Vidal 3, Alicia San Jose 1 and
Antoni Torres 1,*
1 Department of Pneumology, Institut Clinic del Tórax, Hospital Clinic of Barcelona-Institut d’Investigacions
Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Ciber de Enfermedades
Respiratorias (CIBERES), 08036 Barcelona, Spain; catiacilloniz@yahoo.com (C.C.); sanjose@clinic.cat (A.S.J.)
2 Department of Clinical Medicine, Trinity Centre for Health Sciences, Multidisciplinary Intensive Care
Research Organization (MICRO), Welcome Trust-HRB Clinical Research, St James’s Hospital,
St James’s University Hospital, Dublin, Ireland; drmartinloeches@gmail.com
3 Department of Infectious Diseases, Hospital Clinic of Barcelona, 08036 Barcelona, Spain;
carolgv75@hotmail.com
* Correspondence: atorres@clinic.ub.es; Tel.: +34-93-227-5779, Fax: +34-93-227-9813
Academic Editor: Susanna Esposito
Received: 18 October 2016; Accepted: 13 December 2016; Published: 16 December 2016
Abstract: Globally, pneumonia is a serious public health concern and a major cause of mortality
and morbidity. Despite advances in antimicrobial therapies, microbiological diagnostic tests and
prevention measures, pneumonia remains the main cause of death from infectious disease in the
world. An important reason for the increased global mortality is the impact of pneumonia on
chronic diseases, along with the increasing age of the population and the virulence factors of the
causative microorganism. The increasing number of multidrug-resistant bacteria, difficult-to-treat
microorganisms, and the emergence of new pathogens are a major problem for clinicians when
deciding antimicrobial therapy. A key factor for managing and effectively guiding appropriate
antimicrobial therapy is an understanding of the role of the different causative microorganisms in the
etiology of pneumonia, since it has been shown that the adequacy of initial antimicrobial therapy
is a key factor for prognosis in pneumonia. Furthermore, broad-spectrum antibiotic therapies are
sometimes given until microbiological results are available and de-escalation cannot be performed
quickly. This review provides an overview of microbial etiology, resistance patterns, epidemiology
and microbial diagnosis of pneumonia.
Keywords: microbial etiology; pneumonia; diagnosis
1. Introduction
In 2014, the eighth cause of mortality in the United States reported by the National Center for
Health Statistics was influenza and pneumonia together [1]. In children, pneumonia is the single
largest infectious cause of death worldwide. In 2015, pneumonia killed 920,136 children under the age
of 5, accounting for 15% of all deaths of children under five years old [2].
Pneumonia infection is the result of a complex process where the lower respiratory tract suffers
the invasion of an infective microorganism. Pneumonia can be acquired in the community or acquired
in the hospital environment, and can be transmitted by the aspiration of a pathogenic microorganism
or by inhalation of a pathogenic microorganism. It is important to know the role of the pathogenic
microorganism in the etiology of a pneumonia infection in order to provide adequate clinical and
therapeutic management of the patient.
Globally, Streptococcus pneumoniae (pneumococcus) is the most common pathogen causing
community-acquired pneumonia. Pneumococcus was considered one of the 9 bacteria of international
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concern in the recent worldwide report of global antibiotic resistance published by the World Health
Organization (WHO) in 2014 [3]. On the other hand, a wide range of pathogens acquired either from the
patient or from the hospital environment can cause nosocomial pneumonia. However, Gram-negative
bacteria are more frequent than Gram-positive bacteria in these cases.
This review summarizes important features and management issues regarding the
microbial etiology of pneumonia, focusing on epidemiology, pathogenesis, diagnostic testing and
resistance patterns.
2. Microbial Etiology of Community-Acquired Pneumonia (CAP)
2.1. Epidemiology
In 2013, the Global Burden of Disease Study based on data from 188 countries around the world,
reported that lower respiratory tract infection was the second most common cause of death [4].
In Europe, mortality rates for CAP vary widely from country to country, ranging from <1% to 48% [5].
The study by Jain et al. [6] about etiology of CAP showed an increased incidence of CAP with
increasing patient age; the annual incidence of pneumonia in the USA was 24.8 cases per 10,000 adults,
with the highest rates among adults aged between 65 and 79 years of age (63.0 cases per 10,000 adults)
and those aged 80 years or older (164.3 cases per 10,000 adults).
The economic cost related to CAP remains high. A recently published Dutch study that included
195,372 CAP cases reported that the median costs of CAP cases were conditional on patient age and
class of treatment care, varying from €344 per case for patients 0 to 9 years old treated as outpatients,
to €10,284 per episode for 50–64 year olds admitted to the intensive care unit (ICU) [7].
2.2. Causative Microorganism
Several studies on the microbial etiology of CAP have been published in recent years [6,8]. Some
of them showed that microbial causes of CAP differ according to the severity of disease at clinical
presentation [9]. A Spanish study regarding the relationship of microbial etiology of CAP and severity,
concluded that pneumococcus is the most frequent pathogen in all sites of care. The second most
frequent group of pathogens was intracellular microorganisms, followed by polymicrobial cases
(Figure 1).
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Although microbiological diagnosis of CAP is fundamental to ensure appropriate antibiotic
therapy, which is associated with decreasing mortality [10], microbial diagnosis of pneumonia is
achieved in less than 50% of cases and antimicrobial therapy should be empirically administered
in order to avoid the delay in establishing appropriate therapy, associated with significant
mortality [11,12].
Globally, Streptococcus pneumoniae (pneumococcus) is widely accepted as being the most common
pathogen in CAP, usually presented with acute symptoms of lower respiratory tract infection,
historically called “typical presentation”. An estimated prevalence of 19.3% to 34% was reported for
S. pneumoniae in Europe [13,14]. The diagnosis of pneumococcal pneumonia has increased significantly
in recent years, mainly due to the introduction of the pneumococcal urine antigen test (routinely
available from 2000 in most countries). Conversely, the incidence of pneumococcal pneumonia has
probably decreased due to the introduction of pneumococcal vaccines, as well as the decreased rate of
smoking in most countries [15].
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Pneumococcus has several virulence factors; the most important being the polysaccharide capsule.
Differences in chemical and antigenic composition of the pneumococcal capsule result in 93 different
types or serotypes, approximately only 15 of which are involved in the majority of invasive infections.
Serotype 3 is the most common serotype associated with adult pneumococcal infection and it has
been associated with septic shock [16]. Serotypes such as 6A, 6B, 9V, 14, 19A, 19F and 23F are more
common in children. However, in recent years, we have observed a change in the pneumococcal
serotype and genotype distributions related to the introduction of pediatric pneumococcal conjugate
vaccines (PCV7).
Intracellular pathogens are frequent causes of pneumonia [9,17], in these cases the clinical
presentation is “atypical”, characterized by sub–acute symptoms, non-productive cough, low fever,
normal white blood cells count and with frequency associated extrapulmonary manifestations.
However, the incidence is variable, depending in part on the difficulties with microbiological cultures
they grow poorly in standard culture media and culture requires expertise. Moreover, performing
standard serologic tests on all patients with CAP is not common practice. The intracellular pathogens
that are well-established as causes of CAP are: Legionella pneumophila, Mycoplasma pneumoniae,
Chlamydophila pneumoniae, Chlamydophila psittaci and Coxiella burnetii [18,19]. No clinical features exist
that make it possible to distinguish intracellular pathogens from classical pathogens (pneumococcus) in
pneumonia, although extra-pulmonary manifestations are often associated with intracellular pathogens
in CAP [20].
A recent review article [19] reported that severe CAP caused by intracellular pathogens
accounts for approximately 1% to 7% of cases [6,8,21]. Since antimicrobial therapy for severe
pneumonia is empiric and covers typical pathogens and the principal intracellular pathogens, results
of microbiological diagnosis have an important relationship with the clinical prognosis of pneumonia.
Furthermore, co-infection with other pathogens is frequent in severe CAP cases. The study by
Cilloniz et al. [22], which included 362 adult patients with severe CAP, found that 10% of the cases with
defined microbial etiology were caused by intracellular pathogens. Co-infection involving intracellular
pathogens and other pathogens was observed in 30% of cases caused by intracellular pathogens.
The biggest challenge for antimicrobial therapy for infection by intracellular pathogens is that
most antibiotics are unable to access intracellular spaces and reach optimum therapeutic concentrations
within the infected cells.
Respiratory viruses are considered the etiological agent in almost one-third of cases of CAP,
in particular influenza viruses (A and B), rhinoviruses, parainfluenza viruses 1, 2 and 3, and
coronaviruses. Globally, it is estimated that 100 million cases of viral pneumonia occur annually [23].
The improvement of molecular diagnostic techniques has demonstrated the increasing prevalence of
viral pneumonia in recent years. The recently published study by Jain et al. [6] analyzing 2320 cases of
pneumonia where an intensive microbiological diagnosis was applied (particularly viral molecular
techniques), identified microbial etiology in 853 (38%) cases. The three main causal agents found
were respiratory viruses (23%), bacterial etiology (11%) and co-infections (3%). One important issue
regarding this study is that it showed that detection of respiratory viruses in CAP is much more
frequent than was previously thought, thanks to molecular techniques.
Influenza virus (A/B) is usually self-limiting but severe complications (such as pneumonia)
can occur, particularly in high-risk individuals (i.e., elderly patients with comorbidities or
immunosuppressed patients). The influenza A (H1N1) pandemic of 2009–2010 gave us fresh
knowledge of influenza. The World Health Organization estimated approximately 16,000 deaths
between April 2009 and January 2010. The majority of these deaths corresponded to patients with
underlying risk factors, such as metabolic dysfunctions, pregnancy, obesity and immunosuppression,
contributing to worse outcomes [24,25].
In the past 20 years, respiratory syncytial virus (RSV) has been identified as an important cause of
pneumonia in adults, especially in the elderly, where it has become the second most frequent viral
cause. Overall, the rate of RSV as an etiology of CAP is between 2% and 5% throughout the year and
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between 5% and 14% during winter [26–29]. Adults with severe immunodeficiency are at particular
risk of severe RSV infection [30,31].
Aspiration pneumonia is also a common cause of CAP. This etiology is frequently underestimated
because of the difficulties in the diagnosis and in addition the microbiological tests are not usually
applied. The most frequent microorganisms involved in aspiration are anaerobic bacteria and
microaerophilic streptococci from the oral flora. Aspiration pneumonia may be the second most
common etiology of CAP in the subset of patients over 80 years old [32].
2.3. Multidrug-Resistant (MDR) Pathogens in CAP
In CAP, in approximately 6% of the cases a MDR pathogen is involved, the most frequent described
being S. aureus and P. aeruginosa. In a recent European study carry out by Aliberti et al. it was reported
that MDR microorganisms were involved in 3.3% to 7.6% CAP cases in which the most commonly
identified MDR pathogen was methicillin-resistant S. aureus (MRSA) [33]. Community-acquired
methicillin-resistant S. aureus (CA-MRSA) has become an important CAP pathogen in endemic areas.
The presence of the gene for the production of the toxin Panton-Valentine Leukocidin (PVL) is the
main characteristic of CA-MRSA. PVL toxin causes leukocyte destruction and necrosis of the tissues.
Presence of cavitation in the lung of a patient with pneumonia is a frequent characteristic in CA-MRSA,
and is usually associated with skin lesions [34]. Since the recommendation of current international
guidelines for severe CAP is empiric therapy with β-lactam with macrolide or fluoroquinolone, which
may not provide adequate protection against MRSA, microbiological diagnosis of these cases is very
important [35].
P. aeruginosa is not a frequent pathogen in CAP [8,36–38]. However, several studies have reported
that in patients with severe CAP requiring ICU admission, P. aeruginosa was the causative agent in
1.8%–8.3% of the cases, with a case-fatality rate of between 50% and 100% [39–43]. A recently published
study [44] found that 1% of cases were caused by MDR P. aeruginosa. The authors identified the use of
prior antibiotic treatment as the only risk factor associated with CAP caused by MDR P. aeruginosa.
S. pneumoniae, the most common cause of CAP, has increased its resistance to several antibiotics
(cephalosporins, macrolides and fluoroquinolones) worldwide in the last two decades [45–47].
Currently, between 20% and 30% of pneumococcus disease cases worldwide are MDR (resistant
to more than three classes of antibiotics) [48,49]. Nevertheless, it is important to note that therapeutic
failure involving β-lactams has not been reported among patients with pneumococcal pneumonia
who are infected with pneumococci that are not susceptible to β-lactams. A reasonable explanation
for this is that the mechanisms of resistance to penicillin are due to alterations in penicillin-binding
proteins (PBPs), leading to decreased binding affinity. Pharmacodynamic studies show that a time
above minimum inhibitory concentration (MIC) of about 40% of the dosing interval (T > 40% MIC)
is predictive of bacteriological efficacy for β-lactams. Among the oral agents, aminopenicillins and
cephalosporins are able to attain these levels in the lung for fully susceptible strains, and even for
pneumococci with penicillin MICs of 2–4 g/mL.
A recent Spanish study [50] compared clinical outcomes in hospitalized patients with and without
macrolide-resistant pneumococcus and reported that hospitalized patients for macrolide-resistant
pneumococcal pneumonia have the same clinical presentation and outcomes as patients without
macrolide-resistant pneumococcus.
3. Microbial Etiology of Hospital Acquired Pneumonia (HAP)
3.1. Epidemiology
Hospital-acquired (nosocomial) pneumonia (HAP) is defined as a pneumonia not incubating at
the time of hospital admission and occurring 48 h or more after admission [51]. Ventilator associated
pneumonia (VAP) is defined as a pneumonia occurring >48 h after endotracheal intubation [51].
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HAP is the second most frequent nosocomial infection worldwide and is also considered
the main cause of mortality for nosocomial infections. Regarding the consumption of antibiotics
in the hospital, HAP accounts for approximately 50%, these data showing the impact on health
resources [52–55]. Pneumonia that arises more than 48 to 72 h after endotracheal intubation is defined
as Ventilator-associated pneumonia (VAP) and is considered the main nosocomial infection in the
ICU [56–58]. VAP represented approximately 70% to 80% of all cases of HAP acquired in the ICU.
HAP is divided into two groups according to the time of onset from admission [59] and this
concept has been validated in several studies [60]. However, several subsequent studies have
questioned the relationship between the timing of VAP and the risk of MDR pathogens [61,62].
In our opinion this concept is outdated. In addition, the recently published ATS/IDSA guidelines
propose that the presence of risk factors for MDR should take precedence over the distribution between
early and late onset pneumonia [51]. We used this concept in the present review only for a better
comprehension (Figure 2).
(i) Early onset is defined as case development within the first four days of hospitalization.
“Community” microorganisms are the main causes of these cases of pneumonia
(methicillin-sensitive Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, and
anaerobes. This kind of pneumonia is associated with better clinical prognosis.
(ii) Late onset is defined when pneumonia occurs after 5 days of hospitalization. The main pathogens
involved in this kind of pneumonia are methicillin-resistant S. aureus, enteric gram negative
bacilli, P. aeruginosa and non-fermenting bacteria (e.g., A. baumannii, S. maltophilia). Pneumonia
caused by two or more pathogens (polymicrobial) is also frequent [59].
(iii) Early onset HAP tends to have a better prognosis than late onset HAP because of the association
of the latter with MDR organisms.
3.2. Causative Microorganism
Most data concerning the etiology of HAP in ICU refer specially to the VAP population; data on
etiology of non-ventilated intensive care acquired pneumonia (NV-ICUAP) remain limited. The study
by Esperatti et al. [57] analyzed 315 episodes of ICU-acquired pneumonia and found that microbial
etiology between VAP and NV-ICUAP were similar, with the only exception that they observed a
higher proportion of S. pneumoniae in NV-ICUAP cases.
The recent article published by Koulenti et al. [63] on data from 27 ICUs in Europe from the
EU-VAP/CAP study analyzed 2436 patients. Among NP cases, HAP occurred in 20.6%, VAP in 42.7%
and very early-onset VAP (VE-VAP) in 12.7% of cases. Microbial diagnosis was possible in 69.5% of
the suspected cases. The most frequent microorganisms reported were: Enterobacteriaceae, S. aureus,
P. aeruginosa and A. baumannii, and a diagnosis of polymicrobial etiology was reported in 32% of
cases. Methicillin-susceptible S. aureus (27.6% vs. 11.4%), S. pneumoniae (9.0% vs. 2.4%), H. influenzae/
M. catahrralis (13.8% vs. 3.8%) were more frequent pathogens in early-onset pneumonia. The authors
also reported a lower incidence of A. baumannii (11.0% vs. 26.5%) and a trend for a lower proportion
of P. aeruginosa (17.9% vs. 26.1%, p = 0.09) in this group of cases. Other important data in this study
showed that the dominant isolates differed between countries. They reported that in Spain, France,
Belgium and Ireland, S. aureus was the dominant microorganism, whereas for Italy and Portugal it was
P. aeruginosa, for Greece and Turkey it was Acinetobacter sp., and for Germany the dominant pathogen
was Escherichia coli.
An important review article by Jones et al. on the results of the SENTRY Antimicrobial Surveillance
Program (1997–2008) [64] was performed to establish which pathogens were most likely to cause
Hospital acquired bacterial pneumonia (HABP) or ventilated acquired bacterial pneumonia (VABP).
The study indicated that the 6 top pathogens causing 80% of HAP cases were: S. aureus, P. aeruginosa,
Klebsiella spp., Escherichia coli, Acinetobacter spp., and Enterobacter spp. (Figure 2).
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Figure 2. The most commonly identified pathogens in patients with Hospital-Acquired Pneumonia
HABP/VABP (SENTRY Study).
3.2.1. Gram-Negative Pathogens
Gram-negative bacteria are implicated in 50% to 80% of the cases of HAP in an ICU [65]. The most
frequent Gram-negative pathogens associated with HAP include:
(i) Pseudomonas aeruginosa.
(ii) Acinetobacter baumannii.
(iii) Haemophilus influenzae.
(iv) Enterobacteriaceae (Klebsiella pneumoniae, E. coli, Enterobacter species, Serratia species, Proteus
species, etc.).
The study by Micek et al. [66] showed that mortality increased to 42% when the age of the patients
increased, the Chalson score increased, there was inadequate initial antimicrobial treatment, and the
only variable independent for predicted mortality was the use of vasopressors in the case of VAP
where P. aeruginosa was isolated.
3.2.2. Gram-Positive Pathogens
Gram-positive pathogens account for 20% to 30% f HAP cases [67]. Methicillin-resistant and
methicillin sensitive S. aureus, pneumococcus and Streptococcus spp. are the most frequent pathogens.
3.2.3. Polymicrobial Infection
Pneumonia caused by more than two pathoge ic microorganism is defined as p lymicrobial and
approximately 30%–70% of VAP cases are c ns d d to have polymicrobial ri en [63,68,69]. The
st dy by Combes et al. [69] found no differences regarding epidemiology data or clinical outcomes
between monomicrobial cases or polym robia cases.
A study by Ferrer t al. [70], which included 441 cases, reported polymicrobial etiol gy of ICUAP
in 16% of cases with confirmed microbiological etiology. The study also found that the presence
of pleural effusion and the absen e of chronic heart disease w re associated with polymicrobial
pneumonia. P lymicrobial etiology did ot influence the outcome of ICUAP when empiric antibiotic
treatment was frequently appropriate.
3.2.4. Microbial Etiology of Early- and Late-Onset Pneumonia
HAP is divided into two groups according to the time of onset from admission [59] and this
concept has been validated in several studies [60]. We used this concept in the present review only for
a better reader comprehension. However, in our opinion this concept is outdated (Figure 3).
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3.2.5. Multidrug-Resistant Pathogens (MDR)
Antibiotic resistance is a global health problem with major consequences worldwide. The 2016
guidelines on HAP and VAP review several articles regarding risk factors for MDR pathogens.
The guidelines summarize the following risk factors:
(i) Risk factors for MDR HAP: prior intravenous antibiotic treatment within 90 days;
(ii) Risk factors for MDR VAP: prior intravenous antibiotic treatment within 90 days; septic shock at
time of VAP; ARDS preceding VAP; five or more days of hospitalization prior to the occurrence
of VAP; acute renal replacement therapy prior to VAP onset.
The risk factors for specific pathogens were as follows:
Risk factors for P. aeruginosa; MRSA HAP/VAP: prior intravenous antibiotic treatment
within 90 days.
The study by Martin-Loeches et al. [71] addressed the resistance patterns and outcomes in ICUAP
in 343 patients. The authors reported that 35% of cases were caused by MDR pathogens. In this study,
patients who developed ICUAP due to MDR pathogens showed higher ICU-mortality and remained
in the ICU for a longer period compared with non-MDR cases.
4. Laboratory Diagnosis of Pneumonia
4.1. Clinical Samples to Be Collected
Since microbiological diagnosis of pneumonia is an important key factor for a better clinical
outcome, it is very important to follow national and international guidelines. Recommendations
regarding samples and diagnostic tests in pneumonia can be seen in Table 1.
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Table 1. Samples and Diagnostic Testing in Pneumonia.
Condition of
Pneumonia
Blood
Cultures Respiratory Samples
Urinary Antigen
Test for Legionella/
Pneumococcus
Comments
Outpatient Sputum culture
Serology test when pathogens are
suspected through
epidemiological evidence
Hospitalized patients
(ward) × × × Influenza test during influenza season
Hospitalized patients
admitted to ICU ×
BAL/BAS in intubated
patients ×
Serology test when pathogens are
suspected through
epidemiological evidence
Failure of outpatient
antibiotic treatment Sputum culture × Serology for intracellular pathogens
CAP cases who do not
respond to treatment or
suspicion of
uncommon pathogens
×
BAL Mycobacterial and
mycological culture
Nasopharyngeal swab
for respiratory viruses
Hospital
acquired pneumonia × × × Influenza test during influenza season
Ventilator
associated pneumonia × BAS/BAL/mini BAL ×
Abbreviations: BAL (bronchoalveolar lavage); BAS (bronchoaspirate); ICU (intensive care unit); CAP
(community-acquired pneumonia) [3,53].
4.1.1. Community-Acquired Pneumonia
According to CAP guidelines, an optional microbiological diagnostic test in low to mild cases of
CAP is recommended and in special situations it should be selected. In the case of severe CAP it is
recommended to take blood cultures, sputum staining, sputum culture, and the urinary antigen test
for Legionella and pneumococcus. There are some special situations where microbiological tests should
be applied:
(i) Outpatients with failure of antibiotic therapy: sputum culture, urinary antigen test for Legionella
pneumophila and Streptococcus pneumoniae.
(ii) Hospitalized patients with positive urinary antigen test for pneumococcus: sputum and
blood culture.
(iii) Severe obstructive lung disease: sputum culture.
(iv) Pleural effusion: sputum and blood culture, urinary antigen test for pneumococcus and Legionella,
pleural fluid culture.
(v) Cavitary infiltrates: sputum culture (bacteria, fungi and mycobacteria) and blood culture.
(vi) Active alcoholism: sputum and blood culture, urinary antigen test for pneumococcus and Legionella.
(vii) Severe CAP admitted to intensive care unit (ICU): sputum and blood culture, urinary antigen test
for pneumococcus and Legionella, tracheal aspirate or bronchoalveolar lavage culture and viral
studies also need to be performed.
(viii) Epidemiological factor or specific risk factors suggesting pathogen: urinary antigen test for
Legionella (Legionnaires disease), influenza test during influenza season.
Microbiological diagnosis of CAP continues to be based on respiratory samples or blood culture.
The main problems with these conventional methods are the low yield and long turnaround time
(48–72 h) and the fact that previous antibiotic use affects microbiological results [72–74].
Int. J. Mol. Sci. 2016, 17, 2120 10 of 18
4.1.2. Hospital Acquired Pneumonia
For cases of HAP (not-VAP), ATS/IDSA guidelines recommend that microbiological tests should
be performed on respiratory samples obtained non-invasively (spontaneous expectoration, sputum
induction, nasotracheal suctioning in a patient who is unable to cooperate to produce a sputum
sample, and endotracheal aspiration in a patient with HAP who subsequently requires mechanical
ventilation) [51].
For VAP cases, non-invasive sampling (endotracheal aspiration) with semi-quantitative cultures
is recommended. Blood culture is also recommended for all patients with suspected VAP [51].
4.2. Diagnostic Testing for Pneumonia
4.2.1. Conventional Microbiological Diagnosis
Blood and pleural cultures: Performing blood cultures in patients before a previous antimicrobial
treatment has a high specificity but a low positivity (less than 20% of the cases) [35,75]. Pneumococcus
is the main causative agent in blood cultures of patients with CAP [40].
The positivity of blood cultures in patients with HAP varies from 8% to 20%; the role of blood
cultures in the diagnosis of VAP is limited because the spread of the infection to the blood occurs in
<10% of cases [52].
In approximately 40% of CAP cases pleural effusion is present. Thoracentesis is recommended in
these cases since empyema is considered a risk factor for poor outcome [76]. Pneumococcal antigen
detection [77], or even molecular detection [78], are recommended in pleural fluid samples.
Falguera et al. [79] proposed the evaluation of six variables: liver disease, pleuritic pain,
tachycardia, tachypnea, systolic hypotension and absence of prior antibiotic treatment, in order
to predict bacteremia in CAP patients. In this score, for each predictive variable one point was assigned.
A cut-off score of 2 in the derivation cohort was best for identification of the risk of bacteremia. On
the other hand, rates of bacteremia were less than 8% for cases with score ≤1, whereas bacteremia
presented in 14%–63% for cases with a score of 2 in the derivation cohort.
An important study on bacteremia caused by antibiotic-resistant pathogens (ARP) in CAP [80]
reported that the risk factors for ARP bacteremia in CAP patients were; previous antibiotic use and
C-reactive protein < 22.2 mg/dL. The authors also reported that inappropriate therapy was more
frequent in ARP bacteremia compared with other bacteremias (27% and 3%, respectively, p < 0.001).
The authors concluded that antibiotic therapy protected against bacteremia, but specifically increased
the risk of bacteremia from ARP due to the inappropriate coverage of these pathogens.
Sputum stain and culture: Sputum sample collection is performed before patients initiate
antimicrobial therapy. For an increase of microbiological diagnostic accuracy an adequate collection
and transport of the sample is recommended; a good quality sample is considered when the sputum
sample contains less than 10 epithelial cells and more than 25 lymphocyte cells.
In cases of pneumococcal CAP, the sensitivity of the Gram stain is approximately 80% [81] and
the sensitivity of the Gram stain is 78% for pneumonia caused by S. aureus, with specificity between
93%–96% [82].
A presumptive diagnosis is considered when a pathogen is isolated from sputum culture since
children <2 years old and patients with chronic pulmonary diseases frequently present oropharynx
colonization by pneumococci. Endotracheal aspirate is the equivalent of sputum sample in VAP cases
and both samples share the same criteria for quality. To distinguish colonization from infection a
threshold ≥105 colony forming units/mL is recommended in VAP cases [83].
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Urinary Antigen Detection: Urinary Antigen Test: antigens from Legionella serotype 1 and
pneumococcus are renally excreted and can be detected. This detection is not affected by the use of
previous antimicrobial therapy. Sensitivity for pneumococcus detection ranges from 50% to 80% with
reported specificity of 70% to 90%. The most common serogroup detected with urinary antigen test is
Legionella serogroup 1, with sensitivity ranging from 70% to 90% and 99% of specificity.
Since there is a variance regarding the sensitivity and specificity of this test, it was proposed that
concentration of urine may increment the sensitivity and specificity of this test [84]. A recent study by
Saukkoriipi et al. [84] on the evaluation of the urinary antigen test in fresh, frozen and concentrated
urine reported that, for fresh un-concentrated urine samples, the sensitivity for pneumococcal
pneumonia was 63% and specificity was 97%. In the case of frozen and concentrated samples the
sensitivity was 81% with 96% specificity.
4.2.2. Molecular Microbiological Diagnosis
The development and implementation of molecular diagnostic tests for pneumonia has been a
major advance in the microbiological diagnosis of respiratory pathogens in the last ten years [85–88].
Molecular tests help us identify a specific pathogen or help distinguish between bacterial and viral
infection and provide information about antibiotic susceptibility patterns, monitor the response
to antibiotic therapy, assess prognosis, aid antimicrobial stewardship, and give information for
disease surveillance.
A recently published article [89] investigated the utility of a comprehensive molecular diagnostic
approach encompassing 26 respiratory bacterial and viral pathogens, including bacterial quantification
in patients with CAP. The study included 323 cases and reported that the use of molecular techniques
in a single lower respiratory tract sample detected pathogen in 87% of pneumonia cases compared with
39% with culture-based methods. H. influenzae and S. pneumoniae were the most frequent pathogens
reported in this study. Furthermore, 85% of the patients had received antimicrobials in the 72 h before
admission; nonetheless PCR detected bacterial pathogens in 78% of these patients, whereas culture
methods only detected 32% (p <0.001). The authors concluded that comprehensive molecular testing
significantly improved pathogen detection in CAP, even in cases with previous antibiotic treatment.
The molecular platforms for pneumonia approved by the Food Drug Administration (FDA), and
the most recent platforms are summarized in Table 2.
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Table 2. Molecular platforms for pneumonia [79–83].
Platform Pathogens Technology Sensibility/Specificity Time Sample Advantages Disadvantages Approved
Curetis Unyvero
P50 Pneumonia
18 bacterial and fungal
pathogens 22 antibiotic
resistance markers
Multiplex-PCR
cartridge system 81%/99% 4 h Sputum, BAL, BAS
Detection of
resistant patterns
Test limited to a two
samples test per run.
A relatively large amount
of hands-on time
Under
FDA/EC/Under
Singapore
Registration/Under
Chinese Registration
GeneXpertMRSA/SA
Methicillin-resistant
S. aureus (MRSA)
methicillin-sensitive
S. aureus (MSSA)
Multiplex-PCR 99%/72% 1 h Blood, Nasal swabs Minimal technicalexpertise Only detects MRSA/SA FDA/EC
MALDI-TOF 200 microorganisms
Mass spectrometry,
identification of
microorganisms directly
from colonies of bacteria
and fungi
99%–100%/
97%–100% 0.5–1 min
Colonies, positive
blood cultures,
direct samples such
as urine
Rapid and accurate
approach to detect
microorganism
Lack of standardized
assay conditions
GeneXpert
Flu Assay
Influenza A/B
(A/2009H1) multiplex-PCR
97%–100%/
100% 1 h
Nasopharyngeal
swabs, nasal
aspirates and
washes
Minimal technical
expertise
Only detects
influenza viruses FDA/EC
GeneXpert Flu/
RSV Assay Influenza A/B/RSV Multiplex-PCR
97%–100%/
100% 0.5–1 h
Nasopharyngeal
swabs, nasal
aspirates and
washes
Minimal technical
expertise
Only detects influenza
viruses and RSV FDA/EC
FilmArray
Respiratory Panel
Adenovirus;
coronaviruses 229E,
OC43, NL63, HKU1;
metapneumovirus;
influenza A, H3, H1, 2009
H1; parainfluenza
viruses 1, 2, 3, 4; RSV;
rhinovirus/enterovirus B.
pertussis, M. pneumoniae,
C. pneumoniae
An unprocessed
biologic/clinical sample
is subjected to nucleic
acid purification, reverse
transcription, a
high-order nested
multiplex PCR and DNA
melting curve analysis
84%–100%/
98%–100% 1 h
Nasopharyngeal
Swab
Minimal technical
expertise required
Test limited to a single
patient test per run.
Decreased sensitivity for
some adenovirus types
FDA/ EC
Abbreviations: PCR = polymerase chain reaction; MSSA = methicillin sensitive S. aureus; MRSA = methicillin resistant S. aureus; RSV = respiratory syncitial virus; FDA = Food Drug
Administrarion; EC = European Community; DNA = Deoxyribonucleic acid; MALDI-TOF = matrix-assisted laser desorption/ionization time-of-flight.
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5. Conclusions
Microbial identification of pathogens causing pneumonia is an important issue for optimum
clinical management of pneumonia and is a major challenge globally, given the expanding rate
of multidrug-resistant pathogens and the emergence of new pathogens. However, despite the
effort of collecting samples in pneumonia cases, approximately 50% of the cases remain without
microbiological identification using conventional methods and recent studies have shown the
importance of implementing new molecular platforms. We believe that conventional methods, together
with molecular testing, will improve the microbiological diagnosis of pneumonia, thereby improving
clinical management of cases, with shorter time to antibiotic therapy, better targeted antibiotic selection,
more effective de-escalation and improved stewardship for pneumonia patients.
Acknowledgments: Cilloniz is recipient of ERS Short Term Fellowship 2016 and Postdoctoral Junior Grants 2013
Ministerio de Economía y Competitividad España.
Author Contributions: All authors contributed to the manuscript. Catia Cilloniz and Antoni Torres conceived,
designed the article and takes responsibility for the integrity of the data. Catia Cilloniz, Ignacio Martin-Loeches,
Carolina Garcia-Vidal. Alicia San Jose and Antoni Torres. Drafting of the review article. Antoni Torres and
Ignacio Martin-Loeches critical revision of the article for important intellectual content. Alicia San Jose contributed
to acquisition data. All authors had full access to all of the data. Antoni Torres is the guarantor.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviation
CAP Community-acquired pneumonia
EPIC Etiology of Pneumonia in the Community
ARP Antibiotic resistant pathogen
ICU Intensive care unit
RSV Respiratory syncitial virus
MDR Multidrug-resistant
MRSA Methicillin-resistant S. aureus
MSSA Methicillin-sensitive S. aureus
CA-MRSA Community-acquired methicillin-resistant S. aureus
PVL Panton-Valentine leukocidin
PBPs Penicillin-binding proteins
MIC Minimum inhibitory concentration
HAP Hospital Acquired Pneumonia
VAP Ventilator associated pneumonia
NV-ICUAP Non-ventilated intensive care acquired pneumonia
VE-VAP Very early-onset VAP
HABP Hospital acquired bacterial pneumonia
VABP Ventilated acquired bacterial pneumonia
ESBL Extended spectrum β-lactamases
CFU Colony-forming units
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